Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ChemGenex Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

At the moment, chemical genomics is discussed mostly as a hot new approach to drug discovery. Dennis Brown, the founder of ChemGenex Therapeutics Inc. thinks the approach can be applied right now to improve preclinical and clinical drug development--specifically for cancer drugs. His firm is harnessing new methods including gene expression analysis, cellular arrays and information technology to find and assess compounds that already exist. The firm is also leveraging Brown's Rolodex to inform its bioinformatics software. It's gathering insights and tips from medicinal chemists and academic oncologists who've been working with cancer drugs for decades.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts